Technical Trend Overview and Price Movement
As of 2 Feb 2026, Artemis Medicare Services Ltd closed at ₹247.30, a slight dip of 0.02% from the previous close of ₹247.35. The stock’s intraday range spanned from ₹244.00 to ₹256.75, indicating some volatility but limited directional conviction. Over the past 52 weeks, the stock has traded between ₹208.75 and ₹335.90, underscoring a wide price band that investors have navigated amid sectoral and market fluctuations.
The technical trend has shifted from mildly bullish to sideways, signalling a pause in upward momentum and a potential consolidation phase. This shift is corroborated by several key technical indicators that paint a nuanced picture of the stock’s momentum and trend strength.
MACD and RSI: Divergent Signals
The Moving Average Convergence Divergence (MACD) indicator presents a bearish stance on the weekly chart, suggesting that short-term momentum is weakening. The monthly MACD is mildly bearish, indicating that the longer-term trend is also under pressure but not decisively negative. This divergence between weekly and monthly MACD readings highlights a transitional phase where short-term selling pressure is more pronounced than in the broader timeframe.
Conversely, the Relative Strength Index (RSI) offers a mixed view. The weekly RSI currently shows no clear signal, hovering in a neutral zone that neither favours overbought nor oversold conditions. However, the monthly RSI is bullish, implying that on a longer horizon, the stock retains some underlying strength and buying interest. This disparity suggests that while short-term momentum may be subdued, the stock’s medium-term fundamentals or sentiment could still support a recovery.
Moving Averages and Bollinger Bands Indicate Consolidation
Daily moving averages remain mildly bullish, with short-term averages likely positioned above longer-term ones, providing some support to the stock price. This mild bullishness on the daily chart contrasts with the weekly Bollinger Bands, which are bearish, signalling that price volatility is skewed towards downside risk in the near term. The monthly Bollinger Bands, however, are sideways, reinforcing the notion of a consolidation phase without a clear directional bias.
KST and Dow Theory Trends
The Know Sure Thing (KST) indicator, a momentum oscillator, is mildly bearish on both weekly and monthly charts, aligning with the MACD’s cautionary signals. Dow Theory analysis echoes this sentiment with a mildly bearish weekly trend and no definitive trend on the monthly timeframe. These technical assessments collectively suggest that the stock is navigating a period of uncertainty, with neither bulls nor bears firmly in control.
Volume and On-Balance Volume (OBV) Analysis
On-Balance Volume (OBV) readings show no clear trend on either weekly or monthly charts, indicating that volume flows have not decisively favoured buyers or sellers recently. This lack of volume confirmation often accompanies sideways price action and can signal a wait-and-watch phase among market participants.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Comparative Returns and Market Context
Examining Artemis Medicare’s returns relative to the Sensex reveals a mixed performance. Over the past week, the stock surged 9.72%, significantly outperforming the Sensex’s 1.00% decline. However, this short-term strength contrasts with longer-term underperformance. The stock has declined 7.72% over the past month versus a 4.67% drop in the Sensex, and year-to-date returns stand at -8.75%, lagging the Sensex’s -5.28%.
Over a one-year horizon, Artemis Medicare has underperformed sharply, falling 19% while the Sensex gained 5.16%. Yet, the stock’s long-term track record remains impressive, with a 3-year return of 263.41% compared to the Sensex’s 35.67%, and a remarkable 5-year return of 1083.25% versus the Sensex’s 74.40%. This disparity highlights the stock’s strong growth potential tempered by recent volatility and sectoral headwinds.
Market Capitalisation and Mojo Score Update
Artemis Medicare holds a Market Cap Grade of 3, reflecting its mid-cap status within the hospital sector. The company’s Mojo Score has been revised downward from a previous Buy rating to a Hold, effective 1 Feb 2026, with a current score of 60.0. This adjustment signals a more cautious stance by analysts, acknowledging the recent technical deterioration and sideways momentum, while recognising the stock’s underlying quality and sector positioning.
Implications for Investors
The mixed technical signals suggest that investors should approach Artemis Medicare with measured expectations. The mildly bullish daily moving averages and monthly RSI indicate potential for a rebound, but the bearish weekly MACD, KST, and Bollinger Bands warn of possible near-term weakness or consolidation. The sideways monthly Bollinger Bands and neutral OBV further reinforce the likelihood of a trading range rather than a decisive trend.
Given the stock’s recent downgrade to Hold and the sideways technical trend, investors may prefer to wait for clearer confirmation of trend direction before increasing exposure. Those currently holding the stock should monitor key support levels near ₹244 and resistance around ₹257, as a break in either direction could signal the next phase of momentum.
Artemis Medicare Services Ltd or something better? Our SwitchER feature analyzes this small-cap Hospital stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Industry Considerations
Operating within the hospital sector, Artemis Medicare faces sector-specific challenges including regulatory pressures, fluctuating patient volumes, and evolving healthcare policies. The sector’s performance often correlates with broader economic cycles and government healthcare initiatives, which can influence investor sentiment and stock momentum.
Artemis Medicare’s technical indicators suggest that while the company retains long-term growth credentials, short-term headwinds and sector volatility are impacting price action. Investors should consider these factors alongside fundamental analysis when evaluating the stock’s prospects.
Conclusion: Navigating a Transitional Phase
Artemis Medicare Services Ltd is currently in a transitional technical phase, with momentum indicators signalling a shift from mild bullishness to sideways consolidation. The mixed readings from MACD, RSI, moving averages, and other oscillators underscore the need for cautious optimism. While the stock’s long-term returns remain robust, recent price action and technical downgrades suggest investors should monitor developments closely and await clearer trend confirmation before committing additional capital.
In summary, Artemis Medicare’s technical profile reflects a stock at a crossroads, balancing between its strong historical performance and the immediate challenges posed by a complex market environment.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
